RJRefat Jabara

Refat Jabara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Refat Jabara has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 August 2011
      • Vol. 13  (8) , 468-73

    Clinical outcome of patients with chronic heart failure followed in a specialized heart failure center.

    by Israel Gotsman, Donna Zwas, Zehava Zemora, Refat Jabara, Dan Admon, Chaim Lotan, Andre Keren

    Patients with heart failure (HF) have a poor prognosis. Heart failure centers with specialized nurse-supervised management programs have been proposed to improve prognosis. To evaluate the clinical outcome of patients with HF treated at a multidisciplinary HF center of Clalit Health Services in Jerusalem in collaboration with Hadassah University Hospital. We evaluated clinical outcome including hospitalizations and death in all HF patients followed at the HF center for 1 year. Altogether, 324 patients were included and followed at the HF center; 58% were males with a mean age of 76 +/- 11 years, and 58% were in New York Heart Association (NYHA) functional class Ill-IV. The overall 1 year survival rate was 91% and the 1 year hospitalization rate 29%. Comparing patients in the HF center to the whole cohort of patients with a diagnosis of HF (N = 6618) in Clalit Health Services in Jerusalem demonstrated a similar 1 year survival rate: 91% vs. 89% respectively but with a significantly reduced hospitalization rate: 29% vs. 42% respectively (P < 0.01). Cox regression analysis demonstrated that treatment in the HF center was a significant predictor of reduced hospitalization after adjustment for other predictors (hazard ratio 0.65, 95% confidence interval 0.53-0.80, P < 0.0001). A subset of patients that was evaluated (N = 78) showed significantly increased compliance. NYHA class improved in these patients from a mean of 3.1 +/- 0.1 to 2.6 +/- 0.1 after treatment (P < 0.0001). Supervision by dedicated specialized nurses in a HF center increased compliance, improved functional capacity in HF patients, and reduced hospitalization rate. HF centers should be considered part of the standard treatment of patients with symptomatic HF.


  • Impact of the Definition Utilized on the Rate of Contrast-Induced Nephropathy in Percutaneous Coronary Intervention

    by Refat Jabara, Radhika R. Gadesam, Lakshmana K. Pendyala, William D. Knopf, Nicolas Chronos, Jack P. Chen, Kevin Viel, Spencer B. King, Steven V. Manoukian


    • 1 May 2009
      • Vol. 21  (5) , 216-22

    Comparison of the clinical characteristics of apical and non-apical variants of "broken heart" (takotsubo) syndrome in the United States.

    by Refat Jabara, Radhika Gadesam, Lakshmana Pendyala, Nicolas Chronos, Spencer B King, Jack P Chen

    The present study was designed to delineate and compare the clinical characteristics of patients with apical and non-apical takotsubo syndrome in a high-volume U.S. hospital. A comparison between apical and non-apical variants of the "broken heart," or takotsubo syndrome, has not been performed in the United States. From 2004 through 2007, patients with takotsubo syndrome were identified according to the following criteria: acute chest pain with electrocardiographic changes or elevation of cardiac enzymes, absence of significant coronary narrowing, left ventricular (LV) segmental akinesia ("ballooning"), with or without antecedent stressful events. Based upon the location of LV ballooning, the patients were divided into two subgroups: apical and non-apical. Of 38 patients (age 64 +/- 12 years) fulfilling the inclusion criteria, 84% were women, 79% had documented stressors, 76% had apical and 24% non-apical LV ballooning. When compared to non-apical subjects, apical patients presented predominantly with ST-elevation, had a higher incidence of hypertension, had significantly higher levels of Troponin T (8.5 +/- 6.7 ng/ml vs. 3.4 +/- 2.1 ng/ml, respectively; p = 0.032), and lower ejection fraction (31 +/- 9% vs. 43 +/- 5%, respectively; p < 0.001). Severe complications occurred only in apical subjects: pulmonary edema (10.3%), ventricular tachycardia (6.9%), cardiogenic shock (6.9%), LV apical thrombus (3.4%), transient LV outflow tract obstruction (3.4%), and death (3.4%). Apical and non-apical ballooning subgroups may represent different manifestations of a single syndrome. When compared with non-apical ballooning, the apical ballooning group may represent a more severe subset characterized by more heart failure and an increased rate of cardiac complications.


  • Open Access

    Clinical and Angiographic Features of Small Vessel Stenting in the Drug‐Eluting Stent Era

    by Refat Jabara, Marc Gradman, Jack P. Chen, Spencer B. King Iii, Radhika Gadesam, Nicolas A. F. Chronos

    Hypothesis: This study was designed to investigate the clinical and angiographic features and procedural outcomes of small‐vessel stenting in a real‐world experience during the transition era between drug‐eluting stents (DES) and bare‐metal stents (BMS).Methods: Using one of the largest single‐institutional cohorts, this study evaluated all patients who underwent percutaneous coronary intervention (PCI) from 2002 through 2005. Analysis was restricted to patients receiving a single stent or undergoing balloon‐only angioplasty in a single anatomic site. Small‐vessel stents (SVS) were defined as 2.00 to 2.75 mm and large‐vessel stents (LVS) as 3.00 to 4.00 mm in diameter.Results: A total of 19 580 stents were placed in 10 396 patients. Of 6208 patients fulfilling inclusion criteria, 1630 (26.3%) received SVS, and 4578 (73.7%) received LVS. The SVS group had more female (35.5% vs 26.3%, P < .001) and diabetic patients (27.9% vs 24.2%, P < .003) than the LVS group. Compared with LVS, SVS lesions were shorter (14.5 ± 5.8 mm vs 15.7 ± 6.4 mm, P < .0001) and more complex (66% vs 53% class B2/C lesions, P = .041). Indicators of procedural difficulty, including greater contrast volume, number of devices, total inflation time, and fluoroscopy time, were more commonly observed in the SVS group. After adjustment for confounding factors, the incidence of small treatment vessel diameter was significantly higher among the DES vs the BMS group (odds ratio [OR]: = 1.94, 95% confidence interval [CI]: 1.56–2.36).Conclusions: In addition to identifying distinct patient, lesion, and procedural performance characteristics, our study, one of the largest single‐center experiences in small‐vessel PCI, suggests that the availability of DES substantially increased the use of SVS, as opposed to balloon‐only angioplasty, in this anatomically challenging setting. Copyright


  • Passive and Active Polymer Coatings for Intracoronary Stents: Novel Devices to Promote Arterial Healing

    by Lakshmana Pendyala, Refat Jabara, Keith Robinson, Nicolas Chronos

    Coronary stent implantation is the second great advance in the treatment of obstructive coronary artery disease since the introduction of balloon catheter angioplasty. However, in‐stent restenosis (ISR) caused by neointimal hyperplasia has been a major limitation of stents, occurring in up to 30% of cases. Advances in coronary stent technology both in terms of stent design and function and especially drug‐eluting stents (DES) have significantly improved the safety and efficacy of percutaneous coronary intervention (PCI) with stenting, including marked reduction in ISR. This has led to use of DES for increasingly challenging clinical and lesional subsets, with potential for increased risk of stent‐associated complications, especially late stent thrombosis (LST). Because restenosis and stent thrombosis are caused by multiple and often interrelated factors, ideal agents for stent coatings should inhibit thrombus formation, inflammatory reaction, and cellular proliferation, while supporting reendothelialization. To avoid undesirable effects of currently applied (durable) polymers, biocompatible, and bioabsorbable polymers as well as DES delivery systems that minimize polymer burden have been produced and tested. Bioabsorbable stents, both polymeric and metallic, have been developed to decrease potential late complications after stent implantation. Novel strategies to address some of these challenges are in various stages of research and development. In this article we outline developments in the field of passive and active stent coatings and evaluate the ongoing role of such coatings in the contemporary era of DES.


  • Ambulatory discharge after transradial coronary intervention: Preliminary US single-center experience (Same-day TransRadial Intervention and Discharge Evaluation, the STRIDE Study)

    by Refat Jabara, Radhika Gadesam, Lakshmana Pendyala, Nicolas Chronos, Larry V. Crisco, Spencer B. King, Jack P. Chen


  • Novel bioabsorbable salicylate‐based polymer as a drug‐eluting stent coating

    by Refat Jabara, Nicolas Chronos, Keith Robinson

    Background: Permanent polymers used in current drug‐eluting stents (DES) can trigger chronic inflammation and hypersensitivity reactions, which may contribute to the increased risk of late thrombosis and rebound restenosis. Therefore, optimal polymer selection and the use of completely absorbable but biocompatible polymers are expected to minimize these risks. Objectives: We sought to evaluate a novel, potentially innately anti‐inflammatory, bioabsorbable salicylate‐based polymer as a DES coating, in a clinically relevant animal model. Methods: Four types of stents were implanted in pig coronary arteries using QCA to optimize stent apposition: bare metal stents (BMS); salicylic acid/adipic acid bioabsorbable polymer‐only coated metal stents (SA/AA); biostable polymeric sirolimus‐eluting stents (Cypher™); and metal stents coated with salicylic acid/adipic acid bioabsorbable polymer containing sirolimus (SA/AA + S). The dose density of sirolimus was 8.3 μg/mm of stent length (similar to Cypher™) with in vitro studies demonstrating elution over 30 days and complete polymer degradation in 37 days. Animals underwent angiographic restudy and were terminated at 1 month for complete histopathologic and histomorphometric analyses. Results: Both SA/AA + S and Cypher™ stents had significantly lower angiographic % stenosis when compared with BMS and SA/AA polymer‐only groups (6 ± 4% and 5 ± 4% vs. 15 ± 7% and 16 ± 5%, respectively, P < 0.001). Intimal thickness was lower for SA/AA + S and Cypher™ than for BMS (0.14 ± 0.06 and 0.13 ± 0.04 mm vs. 0.23 ± 0.05 mm, respectively, P < 0.001). Histologic % area stenosis was also lower for SA/AA + S and Cypher™ when compared with BMS (22 ± 7% and 23 ± 6% vs. 33 ± 5%, respectively, P < 0.001). There was a strong trend toward reduced inflammatory response in the SA/AA and SA/AA + S when compared with BMS and Cypher™ groups (P = 0.072). Conclusions: This study shows favorable vascular compatibility and efficacy for a novel bioabsorbable salicylate‐based polymer as a DES coating, and supports further research and development of this unique class of polymer materials for applications in cardiovascular devices.


  • Comparison of Multidetector 64-Slice Computed Tomographic Angiography to Coronary Angiography to Assess the Patency of Coronary Artery Bypass Grafts

    by Refat Jabara, Nicolas Chronos, Larry Klein, Steven Eisenberg, Rebecca Allen, Shannon Bradford, Stephen Frohwein


    • 1 April 2007
      • Vol. 9  (4) , 290-3

    Comparison of 4 and 6 French catheters for coronary angiography: real-world modeling.

    by Ronen Durst, Chaim Lotan, Hisham Nassar, Mervin Gotsman, Eli Mor, Boris Varshitzki, Penko Greganski, Refat Jabara, Dan Admon, David Meerkin, et al.

    Femoral artery vascular complications are the most common adverse events following cardiac catheterization. Smaller diameter introducer sheaths and catheters are likely to lower the puncture site complication rate but may hinder visualization. To evaluate the safety and angiographic quality of 4 French catheters. The study was designed to simulate real-life operator-based experience. Diagnostic angiography was performed with either 4F or 6F diagnostic catheters; the size of the catheter used in each patient was predetermined by the day of the month. Patients undergoing 4F and 6F diagnostic angiography were ambulated after 4 and 6 hours, respectively. The following technical parameters were recorded by the operator: ease of introducer sheath insertion, ease of coronary intubation, ease of injection, coronary opacification, collateral flow demonstration, and overall assessment. Adverse events were recorded in all patients and included minor bleeding, major bleeding (necessitating blood transfusion), minor hematoma, major hematoma, pseudo-aneurysm formation and arteriovenous fistula. The study group included 177 patients, of whom 91 were in the 4F arm and 86 in the 6F arm. Demographic and procedural data were similar in both groups. Seventy-seven percent of 6F and 50% of 4F procedures were evaluated as excellent (P < 0.05). This difference was attributed to easier intubation of the coronary ostium and contrast material injection, increased opacification of the coronary arteries, and demonstration of collateral flow with 6F catheters. Complications occurred in 22% of patients treated with 6F catheters and in 10% of those treated with 4F catheters (P = 0.11). Of the 50 patients who switched from 4F to 6F 12% had complications. In patients undergoing diagnostic angiography, the complication rate was 10% vs. 27% (most of them minor) in the 4F and 6F groups, respectively (P < 0.05). Patients catheterized with 4F have fewer complications compared with 6F diagnostic catheters even when ambulated earlier. Although 4F had a reduced quality compared to 6F angiographies, they were evaluated as satisfactory or excellent in quality 85% of the time. 4F catheters have a potential for reduced hospitalization stay and are a good option for primary catheterization in patients not anticipated to undergo coronary intervention.